Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Transplantation

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 85 articles:
HTML format



Single Articles


    March 2023
  1. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    PubMed    


  2. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    PubMed    


    February 2023
  3. LUXENBURGER H, Reeg DB, Lang-Meli J, Reinscheid M, et al
    Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients.
    J Hepatol. 2023 Feb 17:S0168-8278(23)00095-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


    January 2023
  4. FUNDORA Y, Hessheimer AJ, Del Prete L, Maroni L, et al
    Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis.
    J Hepatol. 2023 Jan 20:S0168-8278(23)00018-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


    December 2022
  5. LEE BP, Dodge JL, Terrault NA
    Liver Transplant for Alcohol-Associated Liver Disease Continues to Rise 2-Years into the COVID-19 Pandemic Especially Among Young Adults.
    J Hepatol. 2022 Dec 22:S0168-8278(22)03460-2. doi: 10.1016/j.jhep.2022.
    PubMed    


  6. IVANICS T, Wallace D, Claasen MPAW, Patel MS, et al
    Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada.
    J Hepatol. 2022;77:1607-1618.
    PubMed     Abstract available


    November 2022
  7. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
    Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
    J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
    PubMed    


    September 2022
  8. LASCARIS B, de Meijer VE, Porte RJ
    Normothermic liver machine perfusion as a dynamic platform for regenerative purposes: What does the future have in store for us?
    J Hepatol. 2022;77:825-836.
    PubMed     Abstract available


  9. CHEN ZX, Liu SY, Tong XM
    Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
    J Hepatol. 2022;77:892-893.
    PubMed    


    July 2022
  10. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    


    June 2022
  11. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    PubMed     Abstract available


    May 2022
  12. SESSA M, Lai Q, Germinario G, Ravaioli M, et al
    Authors reply to the Letter to the Editor "Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations".
    J Hepatol. 2022 May 7. pii: S0168-8278(22)00270.
    PubMed    


  13. MUCKE MM, Zeuzem S
    The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far.
    J Hepatol. 2022 May 6. pii: S0168-8278(22)00271.
    PubMed     Abstract available


  14. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    PubMed    


  15. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    PubMed     Abstract available


    April 2022
  16. DAVIDOV Y, Indenbaum V, Tsaraf K, Cohen-Ezra O, et al
    A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00237.
    PubMed     Abstract available


    March 2022
  17. MAGYAR CTJ, Beldi G, Banz V
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
    PubMed    


  18. CHOI JY, Kim JH, Kim JM, Kim HJ, et al
    Outcomes of living liver donors are worse than those of matched healthy controls.
    J Hepatol. 2022;76:628-638.
    PubMed     Abstract available


    February 2022
  19. TONIUTTO P, Falleti E, Cmet S, Cussigh A, et al
    Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00122.
    PubMed     Abstract available


  20. MONTANO-LOZA AJ, Ronca V, Ebadi M, Hansen BE, et al
    Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00067.
    PubMed     Abstract available


  21. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    PubMed     Abstract available


    January 2022
  22. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    PubMed    


  23. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    PubMed    


    December 2021
  24. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    PubMed    


    November 2021
  25. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    PubMed     Abstract available


  26. LEE BT, Fiel MI, Schiano TD
    Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective.
    J Hepatol. 2021;75:1203-1216.
    PubMed     Abstract available


  27. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    PubMed     Abstract available


    October 2021
  28. SCHLEGEL A, van Reeven M, Croome K, Parente A, et al
    A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02110.
    PubMed     Abstract available


  29. RUSSO FP, Izzy M, Rammohan A, Kirchner VA, et al
    Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS).
    J Hepatol. 2021 Oct 12. pii: S0168-8278(21)02107.
    PubMed     Abstract available


  30. RABINOWICH L, Shibolet O, Katchman H
    Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: time for comprehensive data analysis.
    J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02102.
    PubMed    


  31. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    PubMed     Abstract available


    September 2021
  32. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    PubMed    


  33. AGOPIAN VG, Markovic D
    Reply to: correspondence regarding "Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction".
    J Hepatol. 2021;75:732-735.
    PubMed    


  34. EEROLA V, Aberg F, Sallinen V
    An unequivocal formula to calculate L-GrAFT score is needed.
    J Hepatol. 2021;75:731-732.
    PubMed    


    August 2021
  35. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    PubMed     Abstract available


  36. VIONNET J, Miquel R, Abraldes JG, Wall J, et al
    Non-invasive alloimmune risk stratification of long-term liver transplant recipients.
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)02001.
    PubMed     Abstract available


  37. GUARINO M, Cossiga V, Esposito I, Alessandro F, et al
    Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open!
    J Hepatol. 2021 Aug 3. pii: S0168-8278(21)01961.
    PubMed    


    July 2021
  38. PENRICE DD, Havlichek D 3rd, Kamath PS, Simonetto DA, et al
    Outcomes Following Liver Transplant in Adults with Telomere Biology Disorders.
    J Hepatol. 2021 Jul 28. pii: S0168-8278(21)01951.
    PubMed    


  39. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    PubMed    


  40. BURRA P, Samuel D, Sundaram V, Duvoux C, et al
    Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
    J Hepatol. 2021;75 Suppl 1:S178-S190.
    PubMed     Abstract available


  41. ADAMS DH
    EASL recognition award recipient 2021: Prof. Patrizia Burra.
    J Hepatol. 2021;75:5-6.
    PubMed    


  42. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    PubMed     Abstract available


    June 2021
  43. RELA M, Rammohan A
    Why Are There So Many Liver Transplants from Living Donors In Asia And So Few In Europe And The US?
    J Hepatol. 2021 Jun 7. pii: S0168-8278(21)00408.
    PubMed     Abstract available


  44. BERNAL W, McPhail MJ
    Acute liver failure.
    J Hepatol. 2021;74:1489-1490.
    PubMed    


  45. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
    Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    J Hepatol. 2021;74:1355-1361.
    PubMed     Abstract available


    May 2021
  46. MATHURIN P
    Early liver transplantation for acute alcoholic hepatitis: we can't say no.
    J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
    PubMed     Abstract available


  47. GIANNINI EG, Marenco S
    High acceptance rate of COVID-19 vaccination in liver transplant recipients.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00344.
    PubMed    


  48. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    PubMed    


  49. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    PubMed    


  50. DE GASPERI A, Zorzi A
    Cardiac evaluation before liver transplantation: a step forward?
    J Hepatol. 2021 May 10. pii: S0168-8278(21)00299.
    PubMed    


  51. MEDERACKE YS, Nienen M, Jarek M, Geffers R, et al
    T cell receptor repertoires within liver allografts are different to those in the peripheral blood.
    J Hepatol. 2021;74:1167-1175.
    PubMed     Abstract available


    April 2021
  52. BELLI LS, Duvoux C, Artzner T, Bernal W, et al
    Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
    PubMed     Abstract available


  53. RABINOWICH L, Grupper A, Baruch R, Ben-Yehoyada M, et al
    Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00255.
    PubMed     Abstract available


  54. RODRIGUEZ-PERALVAREZ M, Colmenero J, Salcedo M
    Reply to: Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00239.
    PubMed    


  55. AGOPIAN VG, Markovic D, Klintmalm GB, Saracino G, et al
    Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction.
    J Hepatol. 2021;74:881-892.
    PubMed     Abstract available


    March 2021
  56. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    PubMed     Abstract available


  57. JOYE R, Lador F, Aggoun Y, Farhat N, et al
    Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    J Hepatol. 2021;74:742-747.
    PubMed     Abstract available


    February 2021
  58. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available


  59. WEBB GJ, Moon AM, Barnes E, Barritt AS 4th, et al
    Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.
    J Hepatol. 2021 Feb 5. pii: S0168-8278(21)00085.
    PubMed    


    January 2021
  60. DE MARTIN E, Coilly A, Chazouilleres O, Roux O, et al
    Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score.
    J Hepatol. 2021 Jan 24. pii: S0168-8278(21)00041.
    PubMed     Abstract available


  61. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
    CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
    PubMed     Abstract available


  62. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    PubMed     Abstract available


  63. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
    Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
    PubMed     Abstract available


    December 2020
  64. AVOLIO AW, Lai Q, Cillo U, Romagnoli R, et al
    L-GrAFT and EASE scores in liver transplantation. Need for a reciprocal external validation and comparison with other scores.
    J Hepatol. 2020 Dec 16. pii: S0168-8278(20)33848.
    PubMed    


  65. MANKA P, Canbay A, Bechmann LP
    Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
    J Hepatol. 2020;73:1578-1579.
    PubMed    


    November 2020
  66. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    PubMed     Abstract available


  67. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
    A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
    PubMed     Abstract available


  68. AQEL B, Wijarnpreecha K, Pungpapong S, Taner CB, et al
    Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33754.
    PubMed     Abstract available


    August 2020

  69. EASL recommendations on treatment of hepatitis C - Final update of the series.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30548.
    PubMed     Abstract available


    June 2020
  70. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    PubMed     Abstract available


    May 2020
  71. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available


    April 2020
  72. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    PubMed     Abstract available


  73. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available


    March 2020
  74. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    PubMed     Abstract available


  75. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    PubMed     Abstract available


  76. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    PubMed     Abstract available


    February 2020
  77. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
    Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:364-377.
    PubMed     Abstract available


  78. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    PubMed     Abstract available


    July 2019
  79. GOET JC, Floreani A, Verhelst X, Cazzagon N, et al
    Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.
    J Hepatol. 2019 Jul 3. pii: S0168-8278(19)30384.
    PubMed     Abstract available


    June 2019
  80. LIU Y, Lu T, Zhang C, Xu J, et al
    Activation of YAP Attenuates Hepatic Damage and Fibrosis in Liver Ischemia-Reperfusion Injury.
    J Hepatol. 2019 Jun 12. pii: S0168-8278(19)30344.
    PubMed     Abstract available


    May 2019
  81. FONTANELLAS A, Avila MA, Anderson KE, Deybach JC, et al
    Current and innovative emerging therapies for porphyrias with hepatic involvement.
    J Hepatol. 2019 May 15. pii: S0168-8278(19)30282.
    PubMed     Abstract available


  82. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    PubMed     Abstract available


    April 2019
  83. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    PubMed    


  84. KIM SU, Seo YS, Lee HA, Kim MN, et al
    A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30222.
    PubMed     Abstract available


    January 2019
  85. DOYLE A, Gorgen A, Muaddi H, Aravinthan AD, et al
    Outcomes of Radiofrequency Ablation as First-Line Therapy for Hepatocellular Carcinoma less than 3 cm in Potentially Transplantable Patients.
    J Hepatol. 2019 Jan 4. pii: S0168-8278(19)30001.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Transplantation is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: